Natera, Inc. (NASDAQ:NTRA) Director Sells $1,548,926.36 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 9,682 shares of Natera stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, November 14th, Gail Boxer Marcus sold 2,212 shares of Natera stock. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36.

Natera Price Performance

Shares of NTRA opened at $167.26 on Friday. Natera, Inc. has a fifty-two week low of $53.62 and a fifty-two week high of $171.95. The firm’s 50-day simple moving average is $130.72 and its two-hundred day simple moving average is $117.36. The stock has a market cap of $22.08 billion, a PE ratio of -95.03 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.95) EPS. Analysts anticipate that Natera, Inc. will post -1.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of Natera during the first quarter valued at approximately $220,000. Natixis bought a new stake in shares of Natera during the first quarter valued at approximately $758,000. Magnetar Financial LLC raised its holdings in Natera by 52.5% in the 1st quarter. Magnetar Financial LLC now owns 176,643 shares of the medical research company’s stock worth $16,156,000 after acquiring an additional 60,814 shares during the last quarter. Finally, Hood River Capital Management LLC bought a new position in Natera in the 1st quarter valued at approximately $2,821,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several analyst reports. Morgan Stanley upped their price target on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. BTIG Research lifted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group dropped their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Sanford C. Bernstein increased their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.